Literature DB >> 1390701

Allosteric modifiers of hemoglobin: 2-[4-[[(3,5-disubstituted anilino)carbonyl]methyl]phenoxy]-2-methylpropionic acid derivatives that lower the oxygen affinity of hemoglobin in red cell suspensions, in whole blood, and in vivo in rats.

D J Abraham1, F C Wireko, R S Randad, C Poyart, J Kister, B Bohn, J F Liard, M P Kunert.   

Abstract

Two new potent allosteric effectors of hemoglobin, RSR-4 [2-[4-[[(3,5-dichloroanilino)carbonyl]-methyl]phenoxy]-2- methylpropionic acid] and RSR-13 [2-[4-[[(3,5-dimethlanilino)carbonyl]methyl]-phenoxy]-2-methylp rop ionic, are compared to the previously reported compounds L3,5 and L3,4,5 [Lalezari, I., Lalezari, P., Poyart, C., Marden, M., Kister, J., Bohn, B., Fermi, G., & Perutz, M. F. (1990) Biochemistry 29, 1515]. Unlike L3,5 and L3,4,5, RSR-4 and RSR-13 are less impeded by physiological concentrations of serum albumin. RSR-4 has also been shown to be more effective than L3,5 in shifting the allosteric equilibrium of bovine Hb toward the low-affinity T-state. X-ray crystal studies show that both RSR-4 and RSR-13 bind to only one pair of symmetry-related sites in the Hb central water cavity whereas previous studies on L3,5 and L3,4,5 demonstrated a second pair of symmetry-related binding sites near Arg 104 beta. Three major interactions between these allosteric effectors and Hb include the acid group with the guanidinium group of C-terminal Arg 141 alpha, the effector's amide oxygen with the ammonium ion of Lys 99 alpha, and the phi electrons of the halogenated or methylated aromatic ring and Asn 108 beta. No explanation has been found for the difference in number of binding sites observed for RSR-4 and RSR-13 (two sites) compared to L3,5 and L3,4,5 (four sites); also no correlation has been made between the number of binding sites and degree of allosteric shift in the oxygen equilibrium curve.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1390701     DOI: 10.1021/bi00153a005

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  11 in total

1.  High-resolution crystal structure of deoxy hemoglobin complexed with a potent allosteric effector.

Authors:  M K Safo; C M Moure; J C Burnett; G S Joshi; D J Abraham
Journal:  Protein Sci       Date:  2001-05       Impact factor: 6.725

Review 2.  Drugs for increasing oxygen and their potential use in doping: a review.

Authors:  Aurelie Gaudard; Emmanuelle Varlet-Marie; Francoise Bressolle; Michel Audran
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

3.  Two mutations in recombinant Hb beta F41(C7)Y, K82 (EF6)D show additive effects in decreasing oxygen affinity.

Authors:  A Dumoulin; L Kiger; N Griffon; C Vasseur; I Kister; P Génin; M C Marden; J Pagnier; C Poyart
Journal:  Protein Sci       Date:  1996-01       Impact factor: 6.725

4.  Identification of a novel class of covalent modifiers of hemoglobin as potential antisickling agents.

Authors:  A M Omar; M A Mahran; M S Ghatge; N Chowdhury; F H A Bamane; M E El-Araby; O Abdulmalik; M K Safo
Journal:  Org Biomol Chem       Date:  2015-06-14       Impact factor: 3.876

5.  Characterization of diadzein-hemoglobin binding using optical spectroscopy and molecular dynamics simulations.

Authors:  Bidisha Sengupta; Sandipan Chakraborty; Maurice Crawford; Jasmine M Taylor; Laura E Blackmon; Pradip K Biswas; Wolfgang H Kramer
Journal:  Int J Biol Macromol       Date:  2012-05-16       Impact factor: 6.953

6.  Random chemical modification of the oxygen-linked chloride-binding sites of hemoglobin: those in the central dyad axis may influence the transition between deoxy- and oxy-hemoglobin.

Authors:  H Ueno; A M Popowicz; J M Manning
Journal:  J Protein Chem       Date:  1993-10

7.  Preservation of canine myocardial high-energy phosphates during low-flow ischemia with modification of hemoglobin-oxygen affinity.

Authors:  R G Weiss; M A Mejia; D A Kass; A F DiPaula; L C Becker; G Gerstenblith; V P Chacko
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

8.  Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations.

Authors:  R K Brachmann; K Yu; Y Eby; N P Pavletich; J D Boeke
Journal:  EMBO J       Date:  1998-04-01       Impact factor: 11.598

Review 9.  Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin.

Authors:  Martin K Safo; Gregory J Kato
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-21       Impact factor: 3.722

10.  RSR13, an allosteric effector of haemoglobin, and carbogen radiosensitize FSAII and SCCVII tumours in C3H mice.

Authors:  S R Khandelwal; B D Kavanagh; P S Lin; Q T Truong; J Lu; D J Abraham; R K Schmidt-Ullrich
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.